POU6F2-AS2 and AC022126.1 transcripts are highly expressed in lung cancer tissue and is stage independent. (A) Tissue expression of POU6F2-AS2 as profiled by RNA sequencing in lung cancer tissue and adjacent non-tumor lung GSE 81089 dataset). (B) Tissue expression of AC022126.1 as profiled by RNA sequencing in lung cancer tissue and adjacent non-tumor lung GSE 81089 dataset). (C) Association between POU6F2-AS2 expression and tumor stage in NSCLC tumor tissue samples from the GSE 81089 dataset (n= 199 tumor tissue samples and 19 non-tumor lung samples). Significance was tested in 1-way ANOVA. (D) Tissue expression of POU6F2-AS2 as profiled by RT-ddPCR in healthy donors (n= 9) and NSCLC (n= 18) patients, (E) Tissue expression of POU6F2-AS2 as profiled by RT-ddPCR in healthy donors (n= 9) and early stage NSCLC (n= 12) patients, and (F) Tissue expression of POU6F2-AS2 as profiled by RT-ddPCR in healthy donors (n= 9) and late stage NSCLC (n= 7) patients. In (A–F) scatter dot-plots, the line indicates the mean; Student’st-testpvalues are indicated.

POU6F2-AS2 is highly expressed in cfRNA from other solid tumor entities. (A) Plasma expression of POU6F2-AS2 as profiled by total cfRNA sequencing in healthy donors (n= 4) and PDAC (n= 4). (B) Expression of POU6F2-AS2 as profiled by RT-ddPCR in healthy donors’ (n= 22) and PDAC (n= 20) patients’ sera, (C) Expression of POU6F2-AS2 as profiled by RT-ddPCR in healthy donors’ (n= 37) and melanoma (n=12) patients’ plasma, and (D) Expression of POU6F2-AS2 as profiled by RT-ddPCR in healthy donors’ (n= 22) and and bladder cancer (n= 22) patients’ sera. In (A–D) scatter dot-plots, the line indicates the mean; Student’st-testpvalues are reported.